CA2814908A1 - Anticorps utilises pour traiter le vih - Google Patents

Anticorps utilises pour traiter le vih Download PDF

Info

Publication number
CA2814908A1
CA2814908A1 CA 2814908 CA2814908A CA2814908A1 CA 2814908 A1 CA2814908 A1 CA 2814908A1 CA 2814908 CA2814908 CA 2814908 CA 2814908 A CA2814908 A CA 2814908A CA 2814908 A1 CA2814908 A1 CA 2814908A1
Authority
CA
Canada
Prior art keywords
antibody
hiv
seq
cdr
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2814908
Other languages
English (en)
Inventor
Christine Klinguer-Hamour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/913,300 external-priority patent/US9090686B2/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CA2814908A1 publication Critical patent/CA2814908A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA 2814908 2010-10-27 2011-10-27 Anticorps utilises pour traiter le vih Abandoned CA2814908A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/913,300 2010-10-27
US12/913,300 US9090686B2 (en) 2009-04-29 2010-10-27 Antibodies for the treatment of HIV
PCT/EP2011/068905 WO2012055980A1 (fr) 2010-10-27 2011-10-27 Anticorps utilisés pour traiter le vih

Publications (1)

Publication Number Publication Date
CA2814908A1 true CA2814908A1 (fr) 2012-05-03

Family

ID=44913256

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2814908 Abandoned CA2814908A1 (fr) 2010-10-27 2011-10-27 Anticorps utilises pour traiter le vih

Country Status (10)

Country Link
EP (1) EP2632953A1 (fr)
JP (1) JP2014504147A (fr)
KR (1) KR20140009174A (fr)
CN (1) CN103180342A (fr)
AU (1) AU2011322508A1 (fr)
CA (1) CA2814908A1 (fr)
MX (1) MX2013004710A (fr)
RU (1) RU2013122770A (fr)
WO (1) WO2012055980A1 (fr)
ZA (1) ZA201302639B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134547A1 (fr) * 2013-02-28 2014-09-04 Therabiol, Inc. Antigènes du vih et anticorps dirigés contre les antigènes du vih
CA2932788A1 (fr) * 2013-12-08 2015-06-11 Peptcell Limited Antigenes et anticorps anti-vih, compositions, methodes et utilisations
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2009140124A1 (fr) * 2008-05-14 2009-11-19 Eli Lilly And Company Anticorps anti-cxcr4
EP2172485A1 (fr) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Nouveaux anticorps anti CXCR4 et leur utilisation dans le traitement contre le cancer
JP2012158521A (ja) * 2009-04-17 2012-08-23 Kureha Corp 外用剤
EP2246364A1 (fr) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anticorps anti CXCR4 pour le traitement du VIH
EP2371863A1 (fr) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Anticorps humanisé anti CXCR4 pour le traitement du cancer

Also Published As

Publication number Publication date
KR20140009174A (ko) 2014-01-22
MX2013004710A (es) 2013-08-29
ZA201302639B (en) 2013-11-27
JP2014504147A (ja) 2014-02-20
EP2632953A1 (fr) 2013-09-04
RU2013122770A (ru) 2014-12-10
AU2011322508A1 (en) 2013-05-02
CN103180342A (zh) 2013-06-26
WO2012055980A1 (fr) 2012-05-03

Similar Documents

Publication Publication Date Title
AU2010243526B2 (en) Anti CXCR4 antibodies for the treatment of HIV
JP6936361B2 (ja) ヒト免疫不全ウイルス中和抗体
US20220153837A1 (en) Anti-tigit antibodies and their use as therapeutics and diagnostics
KR20160006168A (ko) 인간화 항-cd134(ox40) 항체 및 이의 용도
KR20200063155A (ko) 다중 특이적 항체
KR20140069172A (ko) 항­ｃｄ １３４（ｏｘ４０） 및 이의 용도
JP2021505137A (ja) 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
KR20200041835A (ko) 재조합 이중특이적 항체
AU2022285741A1 (en) Anti-ccr8 antibodies and uses thereof
TWI764291B (zh) 抗tigit抗體及使用方法
KR102165934B1 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
KR20240014058A (ko) 항-cea 항체 및 항-cd137 다중 특이적 항체 및 사용 방법
CA2814908A1 (fr) Anticorps utilises pour traiter le vih
WO2021175954A1 (fr) Anticorps ayant une spécificité pour btnl8 et leurs utilisations

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20171027